These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 14636486)

  • 21. Pharmacological interventions for spasticity following spinal cord injury.
    Taricco M; Adone R; Pagliacci C; Telaro E
    Cochrane Database Syst Rev; 2000; 2000(2):CD001131. PubMed ID: 10796750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological treatment of spasticity in multiple sclerosis].
    Heinzlef O; Monteil-Roch I
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S62-8. PubMed ID: 22721367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
    Stampacchia G; Gerini A; Mazzoleni S
    NeuroRehabilitation; 2016 Apr; 38(4):385-93. PubMed ID: 27061166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrathecal baclofen for muscle spasticity and pain--two case reports.
    Al Khudhairi D; Rababa A; Saddiqui MN
    Middle East J Anaesthesiol; 2006 Jun; 18(5):971-6. PubMed ID: 17094537
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
    Creamer M; Cloud G; Kossmehl P; Yochelson M; Francisco GE; Ward AB; Wissel J; Zampolini M; Abouihia A; Calabrese A; Saltuari L
    Stroke; 2018 Sep; 49(9):2129-2137. PubMed ID: 30354975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
    Kamen L; Henney HR; Runyan JD
    Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review.
    Olvey EL; Armstrong EP; Grizzle AJ
    Clin Ther; 2010 Dec; 32(14):2282-303. PubMed ID: 21353101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    ; Delgado MR; Hirtz D; Aisen M; Ashwal S; Fehlings DL; McLaughlin J; Morrison LA; Shrader MW; Tilton A; Vargus-Adams J
    Neurology; 2010 Jan; 74(4):336-43. PubMed ID: 20101040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients.
    Ben Smail D; Peskine A; Roche N; Mailhan L; Thiébaut I; Bussel B
    Mult Scler; 2006 Feb; 12(1):101-3. PubMed ID: 16459726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intrathecal baclofen in severe spasticity due to multiple sclerosis].
    Sławek J; Zieliński P; Hołub-Kucharska W; Kaniszewska J; Paczkowska M; Słoniewski P
    Neurol Neurochir Pol; 2003; 37(5):1135-42; discussion 1143. PubMed ID: 15174259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
    Stien R; Nordal HJ; Oftedal SI; Slettebø M
    Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Muscle Relaxants for the Treatment of Chronic Pain Associated with Cerebral Palsy.
    Peck J; Urits I; Crane J; McNally A; Noor N; Patel M; Berger AA; Cornett EM; Kassem H; Kaye AD; Viswanath O
    Psychopharmacol Bull; 2020 Oct; 50(4 Suppl 1):142-162. PubMed ID: 33633423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrathecal baclofen in multiple sclerosis: too little, too late?
    Erwin A; Gudesblatt M; Bethoux F; Bennett SE; Koelbel S; Plunkett R; Sadiq S; Stevenson VL; Thomas AM; Tornatore C; Zaffaroni M; Hughes M
    Mult Scler; 2011 May; 17(5):623-9. PubMed ID: 21282321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E; Kuks JB; Meijler WJ
    NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrathecal baclofen pump for spasticity: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(7):1-93. PubMed ID: 23074476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life: effect of reduced spasticity from intrathecal baclofen.
    Gianino JM; York MM; Paice JA; Shott S
    J Neurosci Nurs; 1998 Feb; 30(1):47-54. PubMed ID: 9604822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.
    Rekand T; Grønning M
    J Rehabil Med; 2011 May; 43(6):511-4. PubMed ID: 21533331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity.
    Sadiq SA; Poopatana CA
    J Neurol; 2007 Oct; 254(10):1464-5. PubMed ID: 17932702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.